ROBUST AND BALANCED PIPELINE


Click on the product name to link directly to the product sheet.


Preclinical Phase 1 Phase 2 Phase 3
    AEZS-120 and Erk inhibitor available for out-licensing




















Zoptarelin Doxorubicin:
Rights out-licensed to
Synopharm A-Think
for China, Hong Kong and Macau for endometrial cancer indication

Oncology Oncology Endocrine Therapy Endocrine Therapy



Contact

To inquire about partnering opportunities (in- or out-licensing), please contact our business development group:

Eckard Guenther
Vice President, Business Development
eguenther@aezsinc.com